New drug combo targets brain tumors with genetic flaw
NCT ID NCT04192981
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a drug called GDC-0084 given alongside radiation therapy for people whose cancer has spread to the brain and has a specific genetic mutation (PI3K). The main goal is to find the safest dose of the drug and see if the combination helps shrink tumors. Only 21 participants are enrolled, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GDC-0084 (a drug that targets PI3K pathway mutations) combined with whole brain radiation therapy
What this could lead to
If it works, this could point toward a new treatment option for people with brain metastases that have specific genetic mutations.
What could go wrong
This is a very early phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The combination may not prove effective against the cancer, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAPTIST ALLIANCE - MCI (Data Collection Only)
Miami, Florida, 33143, United States
-
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Consent only)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Consent only)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent only)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, 10604, United States
-
University of Washington (Data Collection AND Data Analysis)
Seattle, Washington, 98109, United States